Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ZG0895
i
Other names:
ZG0895
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Suzhou Zelgen
Drug class:
TLR8 agonist
Related drugs:
‹
imiquimod (4)
SBT6050 (4)
BDC-1001 (2)
BDC-2034 (1)
SBT6290 (1)
VTX 2337 (1)
BDB018 (0)
CV8102 (0)
EIK1001 (0)
GQ1007 (0)
NKTR-262 (0)
imiquimod intravesical (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
imiquimod (4)
SBT6050 (4)
BDC-1001 (2)
BDC-2034 (1)
SBT6290 (1)
VTX 2337 (1)
BDB018 (0)
CV8102 (0)
EIK1001 (0)
GQ1007 (0)
NKTR-262 (0)
imiquimod intravesical (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
›
Associations
News
Trials
Filter by
Latest
9ms
Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Aug 2023
9 months ago
Enrollment open • Trial initiation date • Metastases
|
ZG0895
1year
Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Initiation date: Jul 2023 --> Dec 2023
1 year ago
Trial initiation date • Metastases
|
ZG0895
over1year
Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
over 1 year ago
New P1 trial • Metastases
|
ZG0895
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login